Trial-and-error polypharmacy for ADHD+anxiety leads to interaction fears, side effects (hangover, heart rate, zoning out), and doctor pressure to discontinue effective meds without reliable tracking or shared outcome data.
Patients with ADHD (often inattentive) and comorbid anxiety struggle to find safe, effective medication combinations that manage ADHD focus/productivity while also addressing anxiety, racing thoughts, sleep issues, appetite, and mood without side effects or forced changes by doctors.
people who take adderall (or other ADHD meds) do u also take antidepressants meds and what?
I've had Vyvanse + sertraline (for depression) + mirtazapine.(for sleep) without issue.
commentI've had Vyvanse + sertraline (for depression) + mirtazapine.(for sleep) without issue. It did weird me out because I'm also prescribed sumatriptan to take as-needed for migraines, so that's *four* serotonin-boosting meds. I had to go out of my way to ask the pharmacist if this combo was actually safe, and good thing I did, because he told me I shouldn't take the sumatriptan and mirtazapine on the same day. 🙄)
struggling with the fake "hangover" that mirtazapine is known to give people
comment30mg Adderall XR in the morning (then 20mg in the afternoon), 7.5mg mirtazapine for sleep. I'm struggling with the fake "hangover" that mirtazapine is known to give people, though. I also feel like the Adderall is just making me zone out/lose interest in anything else but doomscrolling. I lose a lot of time to that. Might have to ask to try a different med.
Working adults (25-45) prescribed Adderall/Vyvanse plus antidepressants or sleep aids like mirtazapine who experience anxiety side effects and fear doctor-mandated changes.
Multiple users sharing specific combos (Adderall+Lexapro, Vyvanse+mirtazapine) and expressing doctor change fears plus side effect complaints.
Hyper-focused on ADHD stimulant + anxiety adjunct stacks with productivity/sleep metrics, unlike general drug trackers that lack condition-specific benchmarks.
A private tracking app that logs daily stimulant + anxiety/sleep med combos, side effects, and productivity metrics, then generates doctor-ready reports and anonymized community benchmarks for common stacks like Adderall+Lexapro or Vyvanse+mirtazapine.
Users already invest significant time in forum research and fear losing effective regimens costing hundreds in lost productivity; clear frustration with trial-error and doctor changes shows willingness to pay for better personal data and peer-validated insights.
“Track your ADHD+anxiety med stack and share anonymized outcomes with your doctor in one click.”
A private tracking app that logs daily stimulant + anxiety/sleep med combos, side effects, and productivity metrics, then generates doctor-ready reports and anonymized community benchmarks for common stacks like Adderall+Lexapro or Vyvanse+mirtazapine.
Launch in r/ADHD, r/Anxiety, r/adhdwomen and targeted Facebook groups for ADHD adults; partner with patient advocates for doctor-report templates.
Handling health data requires careful compliance; any perceived advice feature could attract scrutiny.
Users may log inconsistently, leading to unreliable benchmarks that undermine trust.
Anonymized insights need critical mass before becoming valuable, risking early churn.
Physicians may dismiss app-generated summaries, limiting perceived value.
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoThis idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 8/10 against 3 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
It sits at the intersection of "ai-powered", "consultants", "data-management", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.
